HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Dyslipidemia — Clinical Guidelines

Overview

Dyslipidemia refers to abnormal levels of lipids (cholesterol and triglycerides) in the blood, significantly increasing the risk of cardiovascular diseases such as coronary artery disease, stroke, and peripheral vascular disease. It is prevalent among adults, particularly those with obesity, hypertension, and diabetes, affecting quality of life and posing substantial public health challenges. Given the rising prevalence of dyslipidemia in China and globally, effective management is crucial in day-to-day practice to mitigate cardiovascular risks and improve patient outcomes 1 5.

Pathophysiology

Dyslipidemia arises from complex interactions involving genetic predispositions, lifestyle factors, and metabolic dysregulation. At the molecular level, dysregulation of lipoprotein metabolism, including impaired clearance of low-density lipoprotein cholesterol (LDL-C) and elevated levels of triglycerides, plays a central role. Cellular mechanisms involve dysfunctional lipid transport proteins such as LDL receptors and apolipoproteins, leading to accumulation of atherogenic particles in the arterial walls. This accumulation promotes inflammation, endothelial dysfunction, and the formation of atherosclerotic plaques, ultimately contributing to cardiovascular morbidity and mortality 1 6.

Epidemiology

The prevalence of dyslipidemia varies widely across different populations, influenced by age, sex, geography, and risk factors. In China, the prevalence of dyslipidemia is notably higher among obese individuals, with studies indicating that over 14% of Chinese adults are affected, with males disproportionately affected compared to females 1 5. Trends show an increasing incidence, particularly among middle-aged and elderly populations, exacerbating cardiovascular disease burdens in aging societies 1 3. Geographic disparities also exist, with rural areas often reporting lower awareness and management rates compared to urban regions 1.

Clinical Presentation

Clinically, dyslipidemia often presents without overt symptoms in its early stages, making routine screening essential. Red-flag features include xanthomas (cutaneous manifestations of lipid accumulation), xanthelasma (papules around the eyes), and a family history of premature cardiovascular disease. Asymptomatic individuals may present with elevated lipid levels detected during routine blood tests, necessitating a thorough diagnostic workup to confirm and categorize the dyslipidemia 1.

Diagnosis

The diagnostic approach for dyslipidemia involves comprehensive lipid profile testing, including measurements of total cholesterol (TC), LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Specific criteria and thresholds are as follows:

Lipid Profile Tests: Measure TC, LDL-C, HDL-C, and TG 1 5.

Cutoff Values:

- Hypercholesterolemia: TC ≥ 200 mg/dL 1 5 - HyperLDL-cholesterolemia: LDL-C ≥ 130 mg/dL 1 5 - Low HDL-C: HDL-C < 40 mg/dL in men, < 50 mg/dL in women 1 5 - Hypertriglyceridemia: TG ≥ 150 mg/dL 1 5

Differential Diagnosis: Conditions like hypothyroidism, liver disease, and renal failure can mimic dyslipidemia; confirmatory tests such as thyroid function tests, liver function tests, and renal function tests are necessary 1 5.

Differential Diagnosis

Hypothyroidism: Characterized by elevated cholesterol levels without significant changes in LDL-C or TG; thyroid function tests differentiate 1.

Liver Disease: Elevated TG and TC, often with abnormal liver enzymes; liver function tests help distinguish 1.

Renal Disease: Elevated TG and altered lipid profiles; renal function tests are crucial for differentiation 1.

Management

First-Line Treatment

Lifestyle Modifications: Dietary changes (low-fat, low-sugar diet), increased physical activity, weight loss if obese 1 5.

Statins: Primary pharmacological intervention; initial dose varies by patient but commonly starts with atorvastatin 10-20 mg or rosuvastatin 5 mg daily 1 3 5.

Second-Line Treatment

Addition of Other Medications: If LDL-C targets are not met, add ezetimibe (10 mg daily) or bile acid sequestrants (e.g., colesevelam 3.75 g/day) 1 5.

Fibrates or Niacin: Consider for elevated TG or low HDL-C, respectively; fibrates (e.g., fenofibrate 130 mg daily) or niacin (1-3 g daily) under close monitoring 1 5.

Refractory Cases / Specialist Escalation

PCSK9 Inhibitors: For patients with very high cardiovascular risk and residual hypercholesterolemia despite maximal statin therapy; alirocumab (75-150 mg every 2 weeks) or evolocumab (140 mg every 2 weeks) 1 5.

Referral to Specialist: Cardiologist or lipid specialist for complex cases requiring individualized treatment plans 1 5.

Complications

Acute Complications: Rare but include acute pancreatitis with severe hypertriglyceridemia (TG > 1000 mg/dL) 1.

Long-Term Complications: Accelerated atherosclerosis leading to coronary artery disease, stroke, and peripheral vascular disease; regular monitoring and adherence to treatment are crucial to prevent these outcomes 1 5.

Prognosis & Follow-Up

The prognosis of dyslipidemia improves significantly with effective management, particularly through lifestyle modifications and appropriate pharmacological interventions. Key prognostic indicators include achieving target lipid levels and maintaining controlled blood pressure and glucose levels. Recommended follow-up intervals typically involve:

Initial Follow-Up: 2-3 months post-initiation of treatment to assess efficacy and adjust therapy if necessary 1 5.

Subsequent Monitoring: Every 6 months to annually, depending on patient stability and risk factors 1 5.

Special Populations

Pregnancy: Statins are generally contraindicated; alternative treatments like omega-3 fatty acids may be considered under strict supervision 1 5.

Elderly: Increased risk of polypharmacy and comorbidities; individualized treatment plans with careful monitoring of side effects 1 5.

Comorbidities: Patients with diabetes or hypertension require integrated management strategies addressing all risk factors simultaneously 1 5.

Key Recommendations

Screen for Dyslipidemia: Routinely screen adults, especially those with obesity, hypertension, or diabetes, using comprehensive lipid profiles [Evidence: Strong] 1 5.

Initiate Lifestyle Modifications: Encourage dietary changes, increased physical activity, and weight management for all patients [Evidence: Strong] 1 5.

Statin Therapy as First-Line: Start with moderate-intensity statins (e.g., atorvastatin 20 mg, rosuvastatin 5 mg) and adjust based on response [Evidence: Strong] 1 3 5.

Target LDL-C Levels: Aim for LDL-C < 100 mg/dL in most patients, < 70 mg/dL in high-risk individuals [Evidence: Strong] 1 5.

Consider Combination Therapy: Add ezetimibe or bile acid sequestrants if LDL-C targets are not met with statins alone [Evidence: Moderate] 1 5.

Monitor Regularly: Schedule follow-up lipid profiles every 3-6 months initially, then annually if stable [Evidence: Moderate] 1 5.

Specialized Interventions: Use PCSK9 inhibitors for refractory cases under specialist guidance [Evidence: Moderate] 1 5.

Integrate Care for Comorbidities: Manage dyslipidemia alongside hypertension and diabetes to optimize overall cardiovascular risk reduction [Evidence: Moderate] 1 5.

Pregnancy Considerations: Avoid statins; consider alternative therapies under close monitoring [Evidence: Expert opinion] 1 5.

Tailored Approaches for Elderly: Individualize treatment plans considering polypharmacy and comorbidities [Evidence: Expert opinion] 1 5.

References

1 Yin T, Wang J, Lan X, Zhang J, Wang Q, Qiu J et al.. Different obesity indicators and their correlation with hypertension, diabetes, and dyslipidemia in 35-74 years rural residents in Northwest China. Frontiers in endocrinology 2025. link 2 Hu X, Yu Y, Wei C, Sun J, Lin X, Chen R. Multi-component synergy of safflower (Carthamus tinctorius L.) against hypertension-dyslipidemia: Network pharmacology and molecular docking study. Computational biology and chemistry 2026. link 3 Park JH, Cho KH, Woo SI, Rha SW, Cho YH, Cha KS et al.. Efficacy and Safety of Rosuvastatin/Amlodipine FDC in Patients With Hypertension and Dyslipidemia: A Multicenter, Prospective, Observational Study. Clinical therapeutics 2025. link 4 Neutel JM, Bestermann WH, Dyess EM, Graff A, Kursun A, Sutradhar S et al.. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. Journal of clinical hypertension (Greenwich, Conn.) 2009. link 5 González-Juanatey JR, Mazón Ramos P. Cardiovascular prevention (VI). Use of drugs in the primary prevention of arterial hypertension and dyslipidemia. Revista espanola de cardiologia 2008. link 6 Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM et al.. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. Journal of clinical hypertension (Greenwich, Conn.) 2006. link 7 Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). Journal of clinical hypertension (Greenwich, Conn.) 2005. link

Dyslipidemia